🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In the first year of the pandemic, people with severe mental illness had a 50% greater risk of all-cause death following COVID-19 infection over people without serious mental illness, according to results published in the British Journal of Psychiatry. okt.to/29G6j8

In this podcast, Rakesh Jain, MD, MPH, examines the similarities and differences between the 2 medications approved by the FDA for the treatment of tardive dyskinesia, helping to navigate the crucial distinctions that shape treatment decisions. okt.to/5Ptly9

Was anorexia, MDD, or anxiety not linked to ADHD? okt.to/r0SChX

Join Nurse Amber Hoberg, PMHNP-BC, as she discusses how treatment differs between populations, how changes in the brain can affect treatment response, and how clinicians and other mental health professionals can approach this patient population. okt.to/0NXHWR

Incorporating drug-drug interactions and lifestyle factors into pharmacogenomics-guided medication management contributed to improved remission rates in patients with major depressive disorder, according to poster results at Psych Congress. okt.to/l8Z2CN

Dr Vladimir Maletic emphasizes how "a better understanding of underlying pathophysiology leads to better-integrated treatments, which will provide us with better results sooner," and how it can benefit those with neurological and psychiatric disorders.  okt.to/SF7Oe9

Fasedienol, a neuroactive nasal spray, was found to be an effective treatment for social anxiety disorder in a phase 3 trial, according to poster findings at the NEI Congress 2023. This phase 3 study followed promising results in previous trials.  okt.to/BqQKGb

Adult attention-deficit/hyperactivity disorder (ADHD) was associated with an increased risk of dementia, according to cohort study results published in JAMA Network Open.  okt.to/i4LNhm

Combining esketamine nasal spray with an SSRI or an SNRI has emerged as a superior treatment option for treatment-resistant depression. Study results were published in The New England Journal of Medicine. okt.to/ZgwMeq

In a recent trial to study the efficacy and safety of synthetic psilocybin accompanied by psychotherapy to treat individuals with treatment-resistant bipolar type II disorder, 80% of participants met the criteria for remission 12 weeks after treatment. okt.to/vftTsG

MAPS Public Benefit Corporation announced that it has submitted a new drug application to the FDA for the use of MDMA in combination with psychological intervention (including psychotherapy), along with other support services, to treat PTSD. okt.to/2BhFj6

Discover how careful monitoring, proper dosing, and patient education can mitigate associated risks and positively impact long-term therapy outcomes with Julie A. Carbray, PhD, PMHNP-BC. okt.to/iSYIwv

“We need a new brain health paradigm based on neuroscience and hope,” says Daniel G. Amen, MD, CEO and founder of Amen Clinics in Newport Coast, California, and 12-time New York Times bestselling author. okt.to/t3ufZ9

Pop quiz! okt.to/oAIyUn

A poster presented at NEI Congress 2023 suggests the use of aripiprazole lauroxil as a versatile option supported by its pharmacokinetic, efficacy, and safety characteristics. okt.to/JWgBNf

Evidence from 2 noninferiority trials and 2 meta-analyses shows that ketamine and gold-standard ECT actually share similar efficacy in treating treatment-resistant depression, points out a recent column published in JAMA Psychiatry. okt.to/1ZyqAg

The intergenerational transmission of psychiatric conditions appears to be mostly attributable to broader psychopathology comorbidity than specific conditions, suggest study results published in JAMA Network Open. okt.to/jS0lYP

Pop quiz! okt.to/ANp5rT

Is it 1, 2, or 3 hours? okt.to/KS6Tah

BIIB080 reduced biomarkers associated with tau pathophysiology in patients with mild Alzheimer disease, according to results from a phase 1b trial published in JAMA Neurology. okt.to/iD64jE